On the cusp of global eradication

Polio is a highly infectious disease caused by a virus that can invade the nervous system and cause permanent paralysis. Thanks to vaccination efforts, we are closing in on the virus. The number of polio cases per year is down by more than 99 percent since the inception of the Global Polio Eradication Initiative in 1988; wild polio types 2 and 3 have been eradicated; and in late summer 2020, the WHO African Region was certified wild polio-free.

Of the wild types of polio, only type 1 remains in the last polio-endemic countries: Afghanistan and Pakistan.

As the world narrows its focus on stamping out the last pockets of poliovirus, global stakeholders are also laying a necessary foundation for tools that will enable complete eradication and minimize the risk of polio making a comeback.

PATH and partners are working to develop novel oral polio vaccines that have the potential to serve as an improved tool to halt outbreaks. Photo: PATH/Gabe Bienczycki.

Polio vaccines: the state of the field

Improvements in hygiene and sanitation have helped minimize exposure to the polio virus and thus the number of polio cases, but the path to eradication is through vaccination.

Inactivated polio vaccines (IPV) and oral polio vaccines (OPV) have propelled us to historically low levels of polio incidence, but new tools are needed for the last mile of disease eradication.

OPV is highly effective in high-burden regions and during disease outbreaks because it protects the individual and halts person-to-person disease transmission. However, on very rare occasions in under-immunized populations, the live, attenuated (weakened) virus used in OPV can mutate and circulate in a community. This is known as circulating vaccine-derived poliovirus (cVDPV). cVDPVs that develop from the ongoing, necessary use of currently available OPV add a complicating factor to ending polio transmission for good, due to the potential of cVDPVs to cause future outbreaks. However, if a population is fully immunized, they will be protected against both vaccine-derived and wild polioviruses.

IPV is highly effective at preventing disease and does not carry the risk of generating cVDPVs, but it also does not confer the same type of immunity that prevents person-to-person transmission, necessary in controlling outbreaks. It is also much more expensive than OPV and more difficult for untrained health workers to deliver in settings where the vaccines are needed most.

Novel oral polio vaccines: closing polio’s last loophole

To stamp out the last pockets of wild and vaccine-derived polio and protect against potential outbreaks, PATH and partners are advancing novel oral polio vaccine candidates (nOPVs) against poliovirus types 1, 2, and 3. Like the currently available OPVs, the nOPV candidates are designed to prevent person-to-person disease transmission, without carrying the same risk of seeding new vaccine-derived polio cases. Since the attenuated (weakened) type 2 strain in the currently available OPV causes the majority of cVDPV outbreaks, the program advanced research on nOPV2 first.

Based on promising Phase 1 and 2 clinical trial data, and on the urgent need to address cVDPV2 outbreaks, nOPV2 became the first vaccine to receive an Emergency Use Listing (EUL) from the World Health Organization (WHO), through which nearly a billion doses were delivered. Additional clinical and surveillance data paved the way for national licensure in Indonesia and for WHO prequalification in December 2023, ensuring long-term access to nOPV2 for outbreak response.

In collaboration with key global partners, PATH is also advancing research and development of nOPV for polio types 1 and 3.
Ending polio—and maintaining long-term protection

If the global community succeeds in ending polio, it will mark only the second time in history that an infectious disease in humans was eradicated, the first being smallpox in 1979. We are very close, but we will succeed only if we invest in the tools necessary to completely stamp out the virus and ensure strong coverage in communities at greatest risk for outbreaks.

Publications


nOPV program partners

**Bio Farma** manufactures nOPV and applied for the Emergency Use Listing for nOPV2.

**The University of Antwerp** sponsored Phase 1 and 2 trials for nOPV2 and corresponding comparator trials.

**Fighting Infectious Diseases in Emerging Countries** sponsored a Phase 2 trial of nOPV2 and corresponding comparator trials.

**icddr,b** sponsored a Phase 2 clinical trial for nOPV2.

**PATH** sponsored a Phase 3 trial for nOPV2 and is advancing clinical studies of nOPV1, nOPV3, and a multivalent formulation of nOPVs.

**University of California, San Francisco**, the **UK National Institute for Biological Standards and Control** (now part of the Medicines and Healthcare Products Regulatory Agency), the **US Centers for Disease Control and Prevention**, and the **US Food and Drug Administration** developed the nOPV candidates.

The **US Centers for Disease Control and Prevention** led the work for primary laboratory assessment from the clinical trial samples.

**The Bill & Melinda Gates Foundation** provided funding support to research, development and manufacturing activities.

**Global Polio Eradication Initiative** and its partner agencies are coordinating the distribution of nOPV2 to respond to type 2 outbreaks.